Between The Lines: Once Weekly Selinexor, Carfilzomib & Dexamethasone in Carfilzomib Non-Refractory Multiple Myeloma Patients

home / between-the-lines / between-the-lines-once-weekly-selinexor-carfilzomib-and-dexamethasone-in-carfilzomib-non

Dr. Joseph Mikhael and Dr. Hakan Kaya review key efficacy and safety data for the combination of Selinexor, Carfilzomib and Dexamethasone in R/R MM and discuss optimal dosing and adverse event management strategies for selinexor.

Selinexor: Rationale for Use in R/R MM Patients

EP. 1: Selinexor: Rationale for Use in R/R MM Patients

Joseph R. Mikhael, MD;Hakan Kaya, MD
October 13th 2022

Joseph Mikhael, MD, provides a brief overview of the relapsed/refractory multiple myeloma landscape and explains the mechanism of action of selinexor.

Trial Data Review: Selinexor, Carfilzomib, and Dexamethasone in R/R MM

EP. 2: Trial Data Review: Selinexor, Carfilzomib, and Dexamethasone in R/R MM

Joseph R. Mikhael, MD;Hakan Kaya, MD
October 13th 2022

Dr Mikhael reviews the baseline characteristics, study design and key efficacy and safety data of selinexor, carfilzomib, dexamethasone (XKd) in patients with relapsed/refractory multiple myeloma who are non-refractory to carfilzomib.

Clinical Implications: Selinexor, Carfilzomib, and Dexamethasone in R/R MM

EP. 3: Clinical Implications: Selinexor, Carfilzomib, and Dexamethasone in R/R MM

Joseph R. Mikhael, MD;Hakan Kaya, MD
October 20th 2022

Dr Mikhael and Dr Kaya discuss the clinical implications and share their thoughts on the use of selinexor, carfilzomib and dexamethasone in patients with R/R MM.

Adverse Event Management and Dosing Strategies for Selinexor

EP. 4: Adverse Event Management and Dosing Strategies for Selinexor

Joseph R. Mikhael, MD;Hakan Kaya, MD
October 20th 2022

Two experienced clinicians share their thoughts on the safety of selinexor, including how they optimize dosing to prioritize patient comfort.

Selinexor: Clinical Pearls for Current and Future Use in R/R MM

EP. 5: Selinexor: Clinical Pearls for Current and Future Use in R/R MM

Joseph R. Mikhael, MD;Hakan Kaya, MD
October 27th 2022

Dr Joseph Mikhael and Dr Hakan Kaya provide advice for community oncologists who use selinexor and discuss the future of selinexor in patients with R/R MM.

Recap: Selinexor, Carfilzomib, and Dexamethasone for Relapsed/Refractory Multiple Myeloma

EP. 6: Recap: Selinexor, Carfilzomib, and Dexamethasone for Relapsed/Refractory Multiple Myeloma

ONCOLOGY Staff
December 20th 2022

Joseph Mikhael, MD, and Hakan Kaya, MD, review key efficacy and safety data for the combination of selinexor, carfilzomib, and dexamethasone in R/R MM and discuss optimal dosing and adverse event management strategies for selinexor.